Previous 10 | Next 10 |
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK , July 28, 2022 /PRNewswire/ -- ...
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén PR Newswire – Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Bo...
Immunic to Participate in Industry and Scientific Conferences in July PR Newswire NEW YORK , June 28, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology...
Immunic, Inc. (NASDAQ:IMUX) added ~26% in the pre-market on Wednesday on below average volume after the clinical-stage biotech announced the publication of data from a mid-stage trial for its lead candidate IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis (RR...
Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology PR Newswire NEW YORK , June 15, 2022 /PRNewswi...
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June PR Newswire NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selec...
Wall Street brushed off a warning from Microsoft on Thursday to finish the session with notable gains. With employment data on tap for the following day, the Nasdaq climbed nearly 2.7%, while the S&P 500 finished higher by 1.8%. The rally included significant gains in Chewy (NYSE:CHWY). T...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunic (NASDAQ: IMUX ) is falling on clinical trial results. It missed the primary endpoint in a Phase 2 study of vidofludimus calcium. This won’t have it moving forward with a Phase 3 clinical trial of t...
Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...
Immunic (NASDAQ:IMUX) stock lost over 60% of its value on June 2 premarket after the company said its lead asset vidofludimus calcium (IMU-838) failed a phase 2 trial in ulcerative colitis (UC) and that it will not plans further development in UC without a partner. The pha...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...